Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELE-101 in Healthy Adults and Patients with Major Depressive Disorder
NCT05434156Phase 2Active, not recruiting
- Sponsor
- Eleusis
- Start
- Oct 2022
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocin benzoate in major depressive disorder (MDD), sponsored by Eleusis. Started Oct 2022; status: active, not recruiting.
02
Drugs
psilocin benzoate
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05434156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05434156.